These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 22214202)

  • 1. Molecular pathology of familial hypercholesterolemia, related dyslipidemias and therapies beyond the statins.
    Faiz F; Hooper AJ; van Bockxmeer FM
    Crit Rev Clin Lab Sci; 2012; 49(1):1-17. PubMed ID: 22214202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark.
    Jensen HK
    Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The extended abnormalities in lipoprotein metabolism in familial hypercholesterolemia: developing a new framework for future therapies.
    Ooi EM; Barrett PH; Watts GF
    Int J Cardiol; 2013 Oct; 168(3):1811-8. PubMed ID: 23907036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Familial hypercholesterolemia].
    Turpin G; Bruckert E
    Ann Med Interne (Paris); 1999 Dec; 150(8):605-14. PubMed ID: 10686642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
    Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
    J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution.
    Liyanage KE; Burnett JR; Hooper AJ; van Bockxmeer FM
    Crit Rev Clin Lab Sci; 2011; 48(1):1-18. PubMed ID: 21657943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent.
    Wang J; Huff E; Janecka L; Hegele RA
    Hum Mutat; 2001 Oct; 18(4):359. PubMed ID: 11668627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background.
    Choumerianou DM; Dedoussis GV
    Clin Chem Lab Med; 2005; 43(8):793-801. PubMed ID: 16201887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma lipoprotein(a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolemia.
    Miltiadous G; Saougos V; Cariolou M; Elisaf MS
    Ann Clin Lab Sci; 2006; 36(3):353-5. PubMed ID: 16951279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and Predictors of Cholesterol Screening, Awareness, and Statin Treatment Among US Adults With Familial Hypercholesterolemia or Other Forms of Severe Dyslipidemia (1999-2014).
    Bucholz EM; Rodday AM; Kolor K; Khoury MJ; de Ferranti SD
    Circulation; 2018 May; 137(21):2218-2230. PubMed ID: 29581125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of statins in the treatment of diabetic dyslipidemia.
    Berriche O; Amrouche C; Jamoussi H; Blouza S
    Tunis Med; 2010 Feb; 88(2):80-4. PubMed ID: 20415163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins and LDL-cholesterol lowering: an overview.
    Stroes E
    Curr Med Res Opin; 2005; 21 Suppl 6():S9-16. PubMed ID: 16138936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Models for describing relations among the various statin drugs, low-density lipoprotein cholesterol lowering, pleiotropic effects, and cardiovascular risk.
    Robinson JG
    Am J Cardiol; 2008 Apr; 101(7):1009-15. PubMed ID: 18359323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathways and agents for lowering LDL-cholesterol in addition to statins.
    Costet P
    Pharmacol Ther; 2010 Jun; 126(3):263-78. PubMed ID: 20227438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial.
    Koeijvoets KC; Rodenburg J; Hutten BA; Wiegman A; Kastelein JJ; Sijbrands EJ
    Circulation; 2005 Nov; 112(20):3168-73. PubMed ID: 16286607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
    Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
    Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis.
    Hemphill LC
    J Clin Lipidol; 2010; 4(5):346-9. PubMed ID: 21122676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of lipid-lowering treatment on natural history of heterozygous familial hypercholesterolemia in past three decades.
    Elis A; Zhou R; Stein EA
    Am J Cardiol; 2011 Jul; 108(2):223-6. PubMed ID: 21545982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemia.
    Mohrschladt MF; van der Sman-de Beer F; Hofman MK; van der Krabben M; Westendorp RG; Smelt AH
    Eur J Hum Genet; 2005 Jul; 13(7):877-82. PubMed ID: 15856070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.